Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Sunday that it has agreed an additional AI-empowered drug discovery collaboration with China Medical System Holdings Limited (CMS) (HKEX:867) (SGX:8A8) targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.
The two parties aim to jointly advance the co-development of the R&D programme by combining Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&D team and deep therapeutic expertise.
Insilico Medicine is eligible to receive up to approximately CNY1.2bn in milestone payments plus royalties.
The collaboration leverages both parties' complementary strengths across the full value chain, from drug discovery and clinical development to commercialisation.
Raidium introduces AI-powered oncology imaging workflow for US cancer centres
Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
Intensity Therapeutics restarts breast cancer Phase 2 clinical trial
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
HDT Bio Launches Canadian clinical programme for brain cancer treatment
Insilico Medicine and CMS to collaborate further on CNS diseases